Login Register Cart 0
Generic placeholder image

Current Nanomedicine

Editor-in-Chief

ISSN (Print): 2468-1873
ISSN (Online): 2468-1881

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

Iron Oxide Nano Particles and its Applications to Cure HER2-Positive Mediated Breast Cancer

Author(s): Dilpreet Singh*, Balak Das Kurmi, G.S. Sarma, Sankha Bhattacharya and Sanjay Nagdev

Volume 12, Issue 1, 2022

Published on: 19 August, 2022

Page: [17 - 31] Pages: 15

DOI: 10.2174/2468187312666220729160759

Price: $65

Abstract

Background: Breast cancer is the second leading cause of death in women worldwide. The extremely rapid rate of metastasis and the propensity to develop resistance to all non-traditional treatments make them equally difficult to treat, which are the causes of increased morbidity and death in breast melanoma patients. Experts all around the world have been focusing on the first detection of a breast lump so that action can be taken at the earliest possible time. Furthermore, traditional treatment procedures such as chemotherapy, radiation, and local surgical treatment suffer from a slew of drawbacks, including toxicity, normal cell genetic modification, and cancer cell spread to healthy tissues. As a result, new therapy regimens with little toxicity to normal cells must be developed very away.

Methods: Iron oxide nanoparticles are still widely utilized for heat targeting and imaging of breast development cells. Using an external magnetic field, they can be coupled with medicines, proteins, enzymes, antibodies, or nucleotides and delivered to target organs, tissues, or malignancies.

Results: Both in vitro and in vivo, iron oxide nanoparticles are effective as theranostics in treating breast cancer. Furthermore, their interactions with pharmaceuticals or functional biomolecules improve drug delivery efficiency and reduce drug systemic toxicity.

Conclusion: The multipurpose presentations of superparamagnetic iron oxide nanoparticles on the analysis, behavior, and perceiving development of breast disease remedies are emphasized in this assessment. Because of their remarkable superparamagnetic, biocompatible, and biodegradable qualities, they are widely used.

Keywords: Iron oxide nanoparticles, breast cancer, hyperthermia, photothermal therapy, MRI contrast agent, and theranostics.

« Previous Next »
Graphical Abstract

[1]
Gale T. Electricity, Or Ethereal Fire, Considered: 1st. Naturally, as the Agent of Animal and Vegetable Life: 2d. Astronomically, Or as the Agent of Gravitation and Motion: 3d. Medically, Or Its Artificial Use in Diseases: Comprehending Both the Theory and Practice of Medical Electricity: And Demonstrated to be an Infallible Cure of Fever, Inflammation, and Many Other Diseases: Constituting the Best Family Physician Ever Extant. In: Moffitt Lyon. 1802; p. 1610.1920.
[2]
Taimoory SM, Rahdar A, Aliahmad M, et al. The synthesis and characterization of a magnetite nanoparticle with potent antibacterial activity and low mammalian toxicity. J Mol Liq 2018; 265: 96-104.
[http://dx.doi.org/10.1016/j.molliq.2018.05.105]
[3]
Gown AM. Current issues in ER and HER2 testing by IHC in breast cancer. Mod Pathol 2008; 21(2)(Suppl. 2): S8-S15.
[http://dx.doi.org/10.1038/modpathol.2008.34] [PMID: 18437174]
[4]
Saravani R, Sargazi S, Saravani R, Rabbani M, Rahdar A, Taboada P. Newly crocin-coated magnetite nanoparticles induce apoptosis and decrease VEGF expression in breast carcinoma cells. J Drug Deliv Sci Technol 2020; 60: 101987.
[http://dx.doi.org/10.1016/j.jddst.2020.101987]
[5]
An K, Somorjai GA. Size and shape control of metal nanoparticles for reaction selectivity in catalysis. ChemCatChem 2012; 4(10): 1512-24.
[http://dx.doi.org/10.1002/cctc.201200229]
[6]
Ponnamma D, Cabibihan JJ, Rajan M, et al. Synthesis, optimization and applications of ZnO/polymer nanocomposites. Mater Sci Eng C 2019; 98: 1210-40.
[http://dx.doi.org/10.1016/j.msec.2019.01.081] [PMID: 30813004]
[7]
Pelaz B, del Pino P, Maffre P, et al. Surface functionalization of nanoparticles with polyethylene glycol: Effects on protein adsorption and cellular uptake. ACS Nano 2015; 9(7): 6996-7008.
[http://dx.doi.org/10.1021/acsnano.5b01326] [PMID: 26079146]
[8]
Javad Farhangi M, Es-Haghi A, Taghavizadeh Yazdi ME, Rahdar A, Baino F. MOF-mediated synthesis of CuO/CeO2 composite nanoparticles: Characterization and estimation of the cellular toxicity against breast cancer cell line (MCF-7). J Funct Biomater 2021; 12(4): 53.
[http://dx.doi.org/10.3390/jfb12040053] [PMID: 34698230]
[9]
Maeda H. Enhanced permeability and retention (epr) efect: Basis for drug targeting to tumor.Biomedical aspects of drug targeting. Springer, US 2002; pp. 211-28.
[http://dx.doi.org/10.1007/978-1-4757-4627-3_11]
[10]
Meng H, Liong M, Xia T, et al. Engineered design of mesoporous silica nanoparticles to deliver doxorubicin and P-glycoprotein siRNA to overcome drug resistance in a cancer cell line. ACS Nano 2010; 4(8): 4539-50.
[http://dx.doi.org/10.1021/nn100690m] [PMID: 20731437]
[11]
Hassiotou F, Geddes D. Anatomy of the human mammary gland: Current status of knowledge. Clin Anat 2013; 26(1): 29-48.
[http://dx.doi.org/10.1002/ca.22165] [PMID: 22997014]
[12]
Geddes DT. The anatomy of the lactating breast: Latest research and clinical implications. Infant 2007; 3(2): 59-63.
[13]
de la Pared Torácica A. Anatomy of the thoracic wall, axilla and breast. Int J Morphol 2006; 24(4): 691-704.
[14]
Jones RE, Lopez KH. Human reproductive biology. Academic Press, San Biego, CA 2013.
[15]
Heffner LJ, Schust DJ. The reproductive system at a glance. John Wiley & Sons 2010; Vol. 23.
[16]
Burlington K, Arts M. Strong Joints Forever 2009. Available from: https://issuu.com/burlington/docs/1277burlingtonaug2009
[17]
Lee BJ, Adair FE. Traumatic fat necrosis of the female breast and its differentiation from carcinoma. Ann Surg 1924; 80(5): 670-91.
[http://dx.doi.org/10.1097/00000658-192411010-00004] [PMID: 17865126]
[18]
Harding F. Breast cancer: Cause, prevention, cure. Tekline publishing 2006.
[19]
Pires MM. Basal-like breast cancer: Modeling its initiation and characterizing novel EGFR variants. Columbia University 2012.
[20]
Hartman J. Antiproliferative action of estrogen receptor beta and Hes-1 in breast cancer. Bio Med 2008.
[21]
Lakhani SR, Van De Vijver MJ, Jacquemier J, et al. The pathology of familial breast cancer: Predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. J Clin Oncol 2002; 20(9): 2310-8.
[http://dx.doi.org/10.1200/JCO.2002.09.023] [PMID: 11981002]
[22]
Dykxhoorn DM, Wu Y, Xie H, et al. miR-200 enhances mouse breast cancer cell colonization to form distant metastases. PLoS One 2009; 4(9): e7181.
[http://dx.doi.org/10.1371/journal.pone.0007181] [PMID: 19787069]
[23]
Walsh T, Casadei S, Coats KH, et al. Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer. JAMA 2006; 295(12): 1379-88.
[http://dx.doi.org/10.1001/jama.295.12.1379] [PMID: 16551709]
[24]
Pedersen BK, Hoffman-Goetz L. Exercise and the immune system: Regulation, integration, and adaptation. Physiol Rev 2000; 80(3): 1055-81.
[http://dx.doi.org/10.1152/physrev.2000.80.3.1055] [PMID: 10893431]
[25]
Garg AD, Nowis D, Golab J, Vandenabeele P, Krysko DV, Agostinis P. Immunogenic cell death, DAMPs and anticancer therapeutics: An emerging amalgamation. Biochim Biophys Acta 2010; 1805(1): 53-71.
[PMID: 19720113]
[26]
Thoidingjam S, Tiku AB. New developments in breast cancer therapy: Role of iron oxide nanoparticles. Adv Nat Sci Nanosci Nanotechnol 2017; 8(2): 023002.
[http://dx.doi.org/10.1088/2043-6254/aa5e33]
[27]
Hu W. High moment synthetic magnetic nanoparticles for biomedical applications. Stanford University 2009.
[28]
Janousek S, et al. Nanoparticles in health and disease: An overview of nanomaterial hazard, benefit and impact on public health policy-current state and outlook. Front Clin Drug Res Hematol 2015; 2: 176.
[29]
Mushtaq T, Shah AA, Akram W, Yasin NA. Synergistic ameliorative effect of iron oxide nanoparticles and Bacillus subtilis S4 against arsenic toxicity in Cucurbita moschata: Polyamines, antioxidants, and physiochemical studies. Int J Phytoremediation 2020; 22(13): 1408-19.
[http://dx.doi.org/10.1080/15226514.2020.1781052] [PMID: 32574074]
[30]
Park J. Development of magnetic labels for magnetic immunoassays: Towards multiplexed detection of pancreatic cancer markers using giant-magnetoresistive sensor. The University of Utah 2017.
[31]
O.G.. Protein nanostructures. Edible nanostructures: A bottom-up approach.Royal Society of Chemistry Cambridge 2014; pp. 69-113.
[32]
Goya G, Grazu V, Ibarra MR. Magnetic nanoparticles for cancer therapy. Curr Nanosci 2008; 4(1): 1-16.
[http://dx.doi.org/10.2174/157341308783591861]
[33]
Singh D, Bedi N, Tiwary AK. Enhancing solubility of poorly aqueous soluble drugs: Critical appraisal of techniques. J Pharm Investig 2018; 48(5): 509-26.
[http://dx.doi.org/10.1007/s40005-017-0357-1]
[34]
Ansari SAMK, Ficiarà E, Ruffinatti FA, et al. Magnetic iron oxide nanoparticles: Synthesis, characterization and functionalization for biomedical applications in the central nervous system. Materials (Basel) 2019; 12(3): 465.
[http://dx.doi.org/10.3390/ma12030465] [PMID: 30717431]
[35]
Singh D. Self-nano emulsifying drug delivery system: A versatile carrier for lipophilic drugs. Pharm Nanotechnol 2021; 9(3): 166-76.
[http://dx.doi.org/10.2174/2211738509666210422124023] [PMID: 33888054]
[36]
LaGrow AP, Besenhard MO. Experimental considerations for scalable magnetic nanoparticle synthesis and surface functionalization for clinical applications. In: Nguyễn TKT, Ed. Clinical Applications of Magnetic Nanoparticles, Boca Raton. 2018.
[http://dx.doi.org/10.1201/9781315168258-6]
[37]
Vogelstein B, Kinzler KW. Cancer genes and the pathways they control. Nat Med 2004; 10(8): 789-99.
[http://dx.doi.org/10.1038/nm1087] [PMID: 15286780]
[38]
Shachar SS, Deal AM, Weinberg M, et al. Skeletal muscle measures as predictors of toxicity, hospitalization, and survival in patients with metastatic breast cancer receiving taxane-based chemotherapy. Clin Cancer Res 2017; 23(3): 658-65.
[http://dx.doi.org/10.1158/1078-0432.CCR-16-0940] [PMID: 27489287]
[39]
Bagnyukova TV, Serebriiskii IG, Zhou Y, Hopper-Borge EA, Golemis EA, Astsaturov I. Chemotherapy and signaling: How can targeted therapies supercharge cytotoxic agents? Cancer Biol Ther 2010; 10(9): 839-53.
[http://dx.doi.org/10.4161/cbt.10.9.13738] [PMID: 20935499]
[40]
Reslan L. Comparison of the cytotoxic mechanisms of anti-CD20 monoclonal antibodies Rituximab and GA101 in Chronic Lymphocytic Leukemia Human health and pathology. Université Claude Bernard - Lyon I 2010.
[41]
Dukes M. Sex hormones and related compounds, including hormonal contraceptives Side Effects of Drugs Annual. Elsevier 2011; pp. 851-80.
[42]
Waks AG, Winer EP. Breast cancer treatment: A review. JAMA 2019; 321(3): 288-300.
[http://dx.doi.org/10.1001/jama.2018.19323] [PMID: 30667505]
[43]
Bentzen SM. Preventing or reducing late side effects of radiation therapy: Radiobiology meets molecular pathology. Nat Rev Cancer 2006; 6(9): 702-13.
[http://dx.doi.org/10.1038/nrc1950] [PMID: 16929324]
[44]
Deepak P, Siddalingam R, Kumar P, et al. Gene based nanocarrier delivery for the treatment of hepatocellular carcinoma. J Drug Deliv Sci Technol 2020; 59: 101837.
[http://dx.doi.org/10.1016/j.jddst.2020.101837]
[45]
Baronzio GF, Hager ED. Hyperthermia in cancer treatment: A primer. Springer Science & Business Media 2008.
[46]
Hola K, Markova Z, Zoppellaro G, Tucek J, Zboril R. Tailored functionalization of iron oxide nanoparticles for MRI, drug delivery, magnetic separation and immobilization of biosubstances. Biotechnol Adv 2015; 33(6 Pt 2): 1162-76.
[http://dx.doi.org/10.1016/j.biotechadv.2015.02.003] [PMID: 25689073]
[47]
Sharma S, Shrivastava N, Rossi F, Tung LD, Thanh NTK. Nanoparticles-based magnetic and photo induced hyperthermia for cancer treatment. Nano Today 2019; 29: 100795.
[http://dx.doi.org/10.1016/j.nantod.2019.100795]
[48]
Baek S, Singh RK, Khanal D, et al. Smart multifunctional drug delivery towards anticancer therapy harmonized in mesoporous nanoparticles. Nanoscale 2015; 7(34): 14191-216.
[http://dx.doi.org/10.1039/C5NR02730F] [PMID: 26260245]
[49]
Yu MK, Park J, Jon S. Targeting strategies for multifunctional nanoparticles in cancer imaging and therapy. Theranostics 2012; 2(1): 3-44.
[http://dx.doi.org/10.7150/thno.3463] [PMID: 22272217]
[50]
Joseph S. Personality disorders: New symptom-focused drug therapy. Psychology Press 1997.
[51]
Vogel JM. Tunnel vision: The regulation of endocrine disruptors. Policy Sci 2004; 37(3-4): 277-303.
[http://dx.doi.org/10.1007/s11077-005-1764-0]
[52]
Barry Blackwell M, Lond MP. Treating the Brain: An Odyssey. INHN Publisher 2020.
[53]
Estevanato LL, Da Silva JR, Falqueiro AM, et al. Co-nanoencapsulation of magnetic nanoparticles and selol for breast tumor treatment: In vitro evaluation of cytotoxicity and magnetohyperthermia efficacy. Int J Nanomedicine 2012; 7: 5287-99.
[PMID: 23055734]
[54]
Ksiazek I, Karolina S, Elzbieta A, et al. Toxicity studies of selol-An organic selenium (iv) compound-in vitro research. Int J Pharm Pharm Sci 2014; 6(5): 264-9.
[55]
Gao J, Liu W, Xia Y, et al. The promotion of siRNA delivery to breast cancer overexpressing epidermal growth factor receptor through anti-EGFR antibody conjugation by immunoliposomes. Biomaterials 2011; 32(13): 3459-70.
[http://dx.doi.org/10.1016/j.biomaterials.2011.01.034] [PMID: 21296406]
[56]
Sandiford L, Phinikaridou A, Protti A, et al. Bisphosphonate-anchored PEGylation and radiolabeling of superparamagnetic iron oxide: long-circulating nanoparticles for in vivo multimodal (T1 MRI-SPECT) imaging. ACS Nano 2013; 7(1): 500-12.
[http://dx.doi.org/10.1021/nn3046055] [PMID: 23194247]
[57]
Hitchens TK, Liu L, Foley LM, Simplaceanu V, Ahrens ET, Ho C. Combining perfluorocarbon and superparamagnetic iron-oxide cell labeling for improved and expanded applications of cellular MRI. Magn Reson Med 2015; 73(1): 367-75.
[http://dx.doi.org/10.1002/mrm.25120] [PMID: 24478194]
[58]
Zhu Y, Sun Y, Chen Y, et al. In vivo molecular MRI imaging of prostate cancer by targeting PSMA with polypeptide-labeled superparamagnetic iron oxide nanoparticles. Int J Mol Sci 2015; 16(5): 9573-87.
[http://dx.doi.org/10.3390/ijms16059573] [PMID: 25927579]
[59]
McLatchie G, Borley N, Chikwe J. Oxford handbook of clinical surgery. OUP Oxford 2013.
[http://dx.doi.org/10.1093/med/9780199699476.001.0001]
[60]
Welcome MO. Gastrointestinal Physiology. Springer 2018.
[http://dx.doi.org/10.1007/978-3-319-91056-7]
[61]
Wu W, Wu Z, Yu T, Jiang C, Kim WS. Recent progress on magnetic iron oxide nanoparticles: Synthesis, surface functional strategies and biomedical applications. Sci Technol Adv Mater 2015; 16(2): 023501.
[http://dx.doi.org/10.1088/1468-6996/16/2/023501] [PMID: 27877761]
[62]
Tombácz E, Turcu R, Socoliuc V, Vékás L. Magnetic iron oxide nanoparticles: Recent trends in design and synthesis of magnetoresponsive nanosystems. Biochem Biophys Res Commun 2015; 468(3): 442-53.
[http://dx.doi.org/10.1016/j.bbrc.2015.08.030] [PMID: 26275707]
[63]
Rüdiger S, Gross U, Kemnitz E. Non-aqueous sol-gel synthesis of nano-structured metal fluorides. J Fluor Chem 2007; 128(4): 353-68.
[http://dx.doi.org/10.1016/j.jfluchem.2006.11.006]
[64]
Bonvin D, Alexander DTL, Millán A, et al. Tuning properties of iron oxide nanoparticles in aqueous synthesis without ligands to improve MRI relaxivity and SAR. Nanomaterials (Basel) 2017; 7(8): 225.
[http://dx.doi.org/10.3390/nano7080225] [PMID: 28820442]
[65]
Niraula G, Shrivastava N, Akhtar K, Javed Y, Coaquira JAH, Sharma SK. Liquid-Phase Synthesis of Multifunctional Nanomaterials: A Recent Update. In: Sharma S, Javed Y, Eds. Magnetic Nanoheterostructures Nanomedicine and Nanotoxicology. Springer, Cham 2020.
[http://dx.doi.org/10.1007/978-3-030-39923-8_1]
[66]
Leslie-Pelecky DL, Rieke RD. Magnetic properties of nanostructured materials. Chem Mater 1996; 8(8): 1770-83.
[http://dx.doi.org/10.1021/cm960077f]
[67]
Ahmed I, Kamisah Kormin, Rizwan Rajput, Muhammed H Albeirutty, Zulfiqar AR, Jehan Z. The Importance of Iron oxides in Natural Environment and Significance of its Nanoparticles Application. In: Development and Prospective Applications of Nanosci30 Current Nanomedicine and Nanotechnology. Bentham Science Publishers 2018; vol. 2: pp. 218-57.
[http://dx.doi.org/10.2174/9781681086453118020008]
[68]
Hufschmid R, Arami H, Ferguson RM, et al. Synthesis of phase-pure and monodisperse iron oxide nanoparticles by thermal decomposition. Nanoscale 2015; 7(25): 11142-54.
[http://dx.doi.org/10.1039/C5NR01651G] [PMID: 26059262]
[69]
Salavati-Niasari M, Davar F. Synthesis of copper and copper (I) oxide nanoparticles by thermal decomposition of a new precursor. Mater Lett 2009; 63(3-4): 441-3.
[http://dx.doi.org/10.1016/j.matlet.2008.11.023]
[70]
Salek-Maghsoudi A, Vakhshiteh F, Torabi R, et al. Recent advances in biosensor technology in assessment of early diabetes biomarkers. Biosens Bioelectron 2018; 99: 122-35.
[http://dx.doi.org/10.1016/j.bios.2017.07.047] [PMID: 28750336]
[71]
Wacks R. Privacy: A very short introduction. OUP Oxford 2015.
[72]
Prabha G, Raj V. Synthesis and characterization of chitosan-polyvinylpyrrolidone-bovine serum albumin-coated magnetic iron oxide nanoparticles as potential carrier for delivery of tamoxifen. J Indian Chem Soc 2018; 15(4): 871-84.
[73]
He S, Song J, Qu J, Cheng Z. Crucial breakthrough of second near-infrared biological window fluorophores: Design and synthesis toward multimodal imaging and theranostics. Chem Soc Rev 2018; 47(12): 4258-78.
[http://dx.doi.org/10.1039/C8CS00234G] [PMID: 29725670]
[74]
Thanh NT, Green LA. Functionalisation of nanoparticles for biomedical applications. Nano Today 2010; 5(3): 213-30.
[http://dx.doi.org/10.1016/j.nantod.2010.05.003]
[75]
Magro M, Baratella D, Jakubec P, et al. Triggering mechanism for DNA electrical conductivity: Reversible electron transfer between DNA and iron oxide nanoparticles. Adv Funct Mater 2015; 25(12): 1822-31.
[http://dx.doi.org/10.1002/adfm.201404372]
[76]
Karakatsanis A, Daskalakis K, Stålberg P, et al. Superparamagnetic iron oxide nanoparticles as the sole method for sentinel node biopsy detection in patients with breast cancer. Br J Surg 2017; 104(12): 1675-85.
[http://dx.doi.org/10.1002/bjs.10606] [PMID: 28877348]
[77]
Kim D-K, Zhang Y, Voit W, et al. Superparamagnetic iron oxide nanoparticles for bio-medical applications. Scr Mater 2001; 44(8-9): 1713-7.
[http://dx.doi.org/10.1016/S1359-6462(01)00870-3]
[78]
Tanaka S, Kaneti YV, Septiani NLW, et al. A review on iron oxide-based nanoarchitectures for biomedical, energy storage, and environmental applications. Small Methods 2019; 3(5): 1800512.
[http://dx.doi.org/10.1002/smtd.201800512]
[79]
Petros RA, DeSimone JM. Strategies in the design of nanoparticles for therapeutic applications. Nat Rev Drug Discov 2010; 9(8): 615-27.
[http://dx.doi.org/10.1038/nrd2591] [PMID: 20616808]
[80]
Athar M, Das AJ. Therapeutic nanoparticles: State-of-the-art of nanomedicine. Adv Mat Res 2014; 1(1): 25-37.
[81]
Antonelli A, Magnani M. Red blood cells as carriers of iron oxide-based contrast agents for diagnostic applications. J Biomed Nanotechnol 2014; 10(9): 1732-50.
[http://dx.doi.org/10.1166/jbn.2014.1916] [PMID: 25992439]
[82]
El-Boubbou K. Magnetic iron oxide nanoparticles as drug carriers: Preparation, conjugation and delivery. Nanomedicine (Lond) 2018; 13(8): 929-52.
[http://dx.doi.org/10.2217/nnm-2017-0320] [PMID: 29546817]
[83]
Marcee AK. Expanded access to Phase II clinical trials in oncology: A step toward increasing scientific validity and compassion. Food Drug Law J 2008; 63(2): 439-57.
[PMID: 18561471]
[84]
Yang X, Hong H, Grailer JJ, et al. cRGD-functionalized, DOX-conjugated, and ⁶⁴Cu-labeled superparamagnetic iron oxide nanoparticles for targeted anticancer drug delivery and PET/MR imaging. Biomaterials 2011; 32(17): 4151-60.
[http://dx.doi.org/10.1016/j.biomaterials.2011.02.006] [PMID: 21367450]
[85]
Schleich N, Sibret P, Danhier P, et al. Dual anticancer drug/superparamagnetic iron oxide-loaded PLGA-based nanoparticles for cancer therapy and magnetic resonance imaging. Int J Pharm 2013; 447(1-2): 94-101.
[http://dx.doi.org/10.1016/j.ijpharm.2013.02.042] [PMID: 23485340]
[86]
Shkilnyy A, Munnier E, Hervé K, et al. Synthesis and evaluation of novel biocompatible super-paramagnetic iron oxide nanoparticles as magnetic anticancer drug carrier and fluorescence active label. J Phys Chem C 2010; 114(13): 5850-8.
[http://dx.doi.org/10.1021/jp9112188]
[87]
Yang Y, Guo Q, Peng J, et al. Doxorubicin-conjugated heparin-coated superparamagnetic iron oxide nanoparticles for combined anticancer drug delivery and magnetic resonance imaging. J Biomed Nanotechnol 2016; 12(11): 1963-74.
[http://dx.doi.org/10.1166/jbn.2016.2298] [PMID: 29363935]
[88]
Hwang J, Lee E, Kim J, et al. Effective delivery of immunosuppressive drug molecules by silica coated iron oxide nanoparticles. Colloids Surf B Biointerfaces 2016; 142: 290-6.
[http://dx.doi.org/10.1016/j.colsurfb.2016.01.040] [PMID: 26966999]
[89]
Ngobili TA, Daniele MA. Nanoparticles and direct immunosuppression. Exp Biol Med (Maywood) 2016; 241(10): 1064-73.
[http://dx.doi.org/10.1177/1535370216650053] [PMID: 27229901]
[90]
Kauffman KJ, Kanthamneni N, Meenach SA, Pierson BC, Bachelder EM, Ainslie KM. Optimization of rapamycin-loaded acetalated dextran microparticles for immunosuppression. Int J Pharm 2012; 422(1-2): 356-63.
[http://dx.doi.org/10.1016/j.ijpharm.2011.10.034] [PMID: 22037446]
[91]
Vaghela R, Kulkarni PK, Osmani RAM, Bhosale RR, Naga Sravan Kumar Varma V. Recent advances in nanosystems and strategies for managing leishmaniasis. Curr Drug Targets 2017; 18(14): 1598-621.
[http://dx.doi.org/10.2174/1389450117666160401124133] [PMID: 27033193]
[92]
Cho S-J, et al. Zebrafish as an animal model in epilepsy studies with multichannel EEG recordings. Sci Rep 2017; 7(1): 1-10.
[PMID: 28127051]
[93]
Oghabian MA, Jeddi-Tehrani M, Zolfaghari A, Shamsipour F, Khoei S, Amanpour S. Detectability of Her2 positive tumors using monoclonal antibody conjugated iron oxide nanoparticles in MRI. J Nanosci Nanotechnol 2011; 11(6): 5340-4.
[http://dx.doi.org/10.1166/jnn.2011.3775] [PMID: 21770186]
[94]
Artemov D, Mori N, Okollie B, Bhujwalla ZM. MR molecular imaging of the Her-2/neu receptor in breast cancer cells using targeted iron oxide nanoparticles. Magn Reson Med 2003; 49(3): 403-8.
[http://dx.doi.org/10.1002/mrm.10406] [PMID: 12594741]
[95]
Durmus NG, Taylor EN, Kummer KM, Webster TJ. Enhanced efficacy of superparamagnetic iron oxide nanoparticles against antibiotic-resistant biofilms in the presence of metabolites. Adv Mater 2013; 25(40): 5706-13.
[http://dx.doi.org/10.1002/adma.201302627] [PMID: 23963848]
[96]
Taylor EN, Kummer KM, Durmus NG, Leuba K, Tarquinio KM, Webster TJ. Superparamagnetic iron oxide nanoparticles (SPION) for the treatment of antibiotic-resistant biofilms. Small 2012; 8(19): 3016-27.
[http://dx.doi.org/10.1002/smll.201200575] [PMID: 22777831]
[97]
Istrate CM, Holban AM, Grumezescu AM, et al. Iron oxide nanoparticles modulate the interaction of different antibiotics with cellular membranes. Rom J Morphol Embryol 2014; 55(3): 849-56.
[PMID: 25329111]
[98]
Parveen S, Wani AH, Shah MA, Devi HS, Bhat MY, Koka JA. Preparation, characterization and antifungal activity of iron oxide nanoparticles. Microb Pathog 2018; 115: 287-92.
[http://dx.doi.org/10.1016/j.micpath.2017.12.068] [PMID: 29306005]
[99]
Prucek R, Tuček J, Kilianová M, et al. The targeted antibacterial and antifungal properties of magnetic nanocomposite of iron oxide and silver nanoparticles. Biomaterials 2011; 32(21): 4704-13.
[http://dx.doi.org/10.1016/j.biomaterials.2011.03.039] [PMID: 21507482]
[100]
Gupta AK, Gupta M. Synthesis and surface engineering of iron oxide nanoparticles for biomedical applications. Biomaterials 2005; 26(18): 3995-4021.
[http://dx.doi.org/10.1016/j.biomaterials.2004.10.012]
[101]
Rowley TF, Al-Shamkhani A. Stimulation by soluble CD70 promotes strong primary and secondary CD8+ cytotoxic T cell responses in vivo. J Immunol 2004; 172(10): 6039-46.
[http://dx.doi.org/10.4049/jimmunol.172.10.6039] [PMID: 15128787]
[102]
Gupta AK, Rohan RN, Vikas DV, Mona G. Recent advances on surface engineering of magnetic iron oxide nanoparticles and their biomedical applications. Nanomedicine 2007; 2(1)
[http://dx.doi.org/10.2217/17435889.2.1.23]
[103]
Amstad E, Textor M, Reimhult E. Stabilization and functionalization of iron oxide nanoparticles for biomedical applications. Nanoscale 2011; 3(7): 2819-43.
[http://dx.doi.org/10.1039/c1nr10173k] [PMID: 21629911]
[104]
Silva AC, Oliveira TR, Mamani JB, et al. Application of hyperthermia induced by superparamagnetic iron oxide nanoparticles in glioma treatment. Int J Nanomedicine 2011; 6: 591-603.
[PMID: 21674016]
[105]
Espinosa A, Di Corato R, Kolosnjaj-Tabi J, Flaud P, Pellegrino T, Wilhelm C. Duality of iron oxide nanoparticles in cancer therapy: Amplification of heating efficiency by magnetic hyperthermia and photothermal bimodal treatment. ACS Nano 2016; 10(2): 2436-46.
[http://dx.doi.org/10.1021/acsnano.5b07249] [PMID: 26766814]
[106]
Gill SS, Tuteja N. Reactive oxygen species and antioxidant machinery in abiotic stress tolerance in crop plants. Plant Physiol Biochem 2010; 48(12): 909-30.
[http://dx.doi.org/10.1016/j.plaphy.2010.08.016] [PMID: 20870416]
[107]
Manton KG, Volovik S, Kulminski A. ROS effects on neurodegeneration in Alzheimer’s disease and related disorders: On environmental stresses of ionizing radiation. Curr Alzheimer Res 2004; 1(4): 277-93.
[http://dx.doi.org/10.2174/1567205043332036] [PMID: 15975057]
[108]
Abdal Dayem A, Hossain MK, Lee SB, et al. The role of reactive oxygen species (ROS) in the biological activities of metallic nanoparticles. Int J Mol Sci 2017; 18(1): 120.
[http://dx.doi.org/10.3390/ijms18010120] [PMID: 28075405]
[109]
Lim E-K, Kim T, Paik S, Haam S, Huh YM, Lee K. Nanomaterials for theranostics: Recent advances and future challenges. Chem Rev 2015; 115(1): 327-94.
[http://dx.doi.org/10.1021/cr300213b] [PMID: 25423180]
[110]
Bhuyan BK, Day KJ, Edgerton CE, Ogunbase O. Sensitivity of different cell lines and of different phases in the cell cycle to hyperthermia. Cancer Res 1977; 37(10): 3780-4.
[PMID: 561655]
[111]
Arias LS, Pessan JP, Vieira APM, Lima TMT, Delbem ACB, Monteiro DR. Iron oxide nanoparticles for biomedical applications: A perspective on synthesis, drugs, antimicrobial activity, and toxicity. Antibiotics (Basel) 2018; 7(2): 46.
[http://dx.doi.org/10.3390/antibiotics7020046] [PMID: 29890753]
[112]
Joris F, Manshian BB, Peynshaert K, De Smedt SC, Braeckmans K, Soenen SJ. Assessing nanoparticle toxicity in cell-based assays: Influence of cell culture parameters and optimized models for bridging the in vitro-in vivo gap. Chem Soc Rev 2013; 42(21): 8339-59.
[http://dx.doi.org/10.1039/c3cs60145e] [PMID: 23877583]
[113]
Thomas RG, Unnithan AR, Moon MJ, et al. Electromagnetic manipulation enabled calcium alginate Janus microsphere for targeted delivery of mesenchymal stem cells. Int J Biol Macromol 2018; 110: 465-71.
[http://dx.doi.org/10.1016/j.ijbiomac.2018.01.003] [PMID: 29355634]
[114]
Reddy LH, Arias JL, Nicolas J, Couvreur P. Magnetic nanoparticles: Design and characterization, toxicity and biocompatibility, pharmaceutical and biomedical applications. Chem Rev 2012; 112(11): 5818-78.
[http://dx.doi.org/10.1021/cr300068p] [PMID: 23043508]
[115]
Deng J, Gao C. Recent advances in interactions of designed nanoparticles and cells with respect to cellular uptake, intracellular fate, degradation and cytotoxicity. Nanotechnology 2016; 27(41): 412002.
[http://dx.doi.org/10.1088/0957-4484/27/41/412002] [PMID: 27609340]
[116]
Soenen SJ, Rivera-Gil P, Montenegro J-M, Parak WJ, De Smedt SC, Braeckmans K. Cellular toxicity of inorganic nanoparticles: Common aspects and guidelines for improved nanotoxicity evaluation. Nano Today 2011; 6(5): 446-65.
[http://dx.doi.org/10.1016/j.nantod.2011.08.001]
[117]
Feng Q, Liu Y, Huang J, Chen K, Huang J, Xiao K. Uptake, distribution, clearance, and toxicity of iron oxide nanoparticles with different sizes and coatings. Sci Rep 2018; 8(1): 2082.
[http://dx.doi.org/10.1038/s41598-018-19628-z] [PMID: 29391477]
[118]
Sabareeswaran A. Cellular and molecular effects of surface modified magnetic nanoparticles in Rat model SCTIMST 2015 Available from: http://dspace.sctimst.ac.in/xmlui/handle/123456789/2896
[119]
da Silva PB, Machado RTA, Pironi AM, et al. Recent advances in the use of metallic nanoparticles with antitumoral action - Review. Curr Med Chem 2019; 26(12): 2108-46.
[http://dx.doi.org/10.2174/0929867325666180214102918] [PMID: 29446728]
[120]
Levin-Reisman I, Ronin I, Gefen O, Braniss I, Shoresh N, Balaban NQ. Antibiotic tolerance facilitates the evolution of resistance. Science 2017; 355(6327): 826-30.
[http://dx.doi.org/10.1126/science.aaj2191] [PMID: 28183996]
[121]
Alegret N, Criado A, Prato M. Recent advances of graphene-based hybrids with magnetic nanoparticles for biomedical applications. Curr Med Chem 2017; 24(5): 529-36.
[http://dx.doi.org/10.2174/0929867323666161216144218] [PMID: 27993110]
[122]
Jansen JP, Fleurence R, Devine B, et al. Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: Report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: Part 1. Value Health 2011; 14(4): 417-28.
[http://dx.doi.org/10.1016/j.jval.2011.04.002] [PMID: 21669366]
[123]
Wigger H. Current and future product applications of iron oxide and silver nanoparticles. In: Environmental Release of and Exposure to Iron Oxide and Silver Nanoparticles. Springer 2017; pp. 89-146.
[http://dx.doi.org/10.1007/978-3-658-16791-2_5]
[124]
de Sousa Cunha F, Dos Santos Pereira LN, de Costa E. Silva TP, de Sousa Luz RA, Nogueira MA. Development of nanoparticulate systems with action in breast and ovarian cancer: Nanotheragnostics. J Drug Target 2019; 27(7): 732-41.
[http://dx.doi.org/10.1080/1061186X.2018.1523418] [PMID: 30207742]

Rights & Permissions Print Cite
Article Metrics
3
© 2024 Bentham Science Publishers | Privacy Policy